Renovo, plc.

From Wikipedia, the free encyclopedia

Renovo, plc.
Type	Public (LSE: RNVO)
Founded	October 2000
Headquarters	Manchester, UK
Key people	Mark Ferguson (CEO) Sharon O'Kane
Industry	Biotechnology
Products	4 in clinical development
Website	www.renovo.com

Renovo, plc. (LSE: RNVO) is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research^[1], and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"^[2] in 2009.

The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes^[3].

[edit] Products

Currently the company doesn't have a marketed product, though its pipeline includes one drug in phase III clinical development, three drugs in phase II clinical development, and numerous pre-clinical candidates.

Drug	Phase	Action
Juvista	Phase II Clinical trial	Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring
Zesteem	Phase III Clinical trial	Accelerates the re-epithelialization of the skin following wounding
Prevascar	Phase II Clinical trial	Injected to the wound margins around the time of surgery causes a reduction of scarring
Juvidex	Phase II Clinical trial	Accelerates the re-epithelialization in split thickness skin graft donor sites